Circulating Tumor Cells Enriched by the Depletion of Leukocytes with Bi-Antibodies in Non-Small Cell Lung Cancer: Potential Clinical Application.
It has been considered that the detection methods for circulating tumor cells (CTCs) based on epithelial cell adhesion molecule (EpCAM) underestimate the number of CTCs and may miss a metastatic subpopulation with cancer stem cell (CSC) properties. Therefore, we investigated EpCAM-positive and -nega...
Main Authors: | , , , , , , , , , , , , |
---|---|
Format: | Article |
Language: | English |
Published: |
Public Library of Science (PLoS)
2015-01-01
|
Series: | PLoS ONE |
Online Access: | http://europepmc.org/articles/PMC4552861?pdf=render |
id |
doaj-4eb52c08845c400ca34aa18a64148821 |
---|---|
record_format |
Article |
spelling |
doaj-4eb52c08845c400ca34aa18a641488212020-11-25T00:23:38ZengPublic Library of Science (PLoS)PLoS ONE1932-62032015-01-01108e013707610.1371/journal.pone.0137076Circulating Tumor Cells Enriched by the Depletion of Leukocytes with Bi-Antibodies in Non-Small Cell Lung Cancer: Potential Clinical Application.Jian YinYi WangHanlu YinWenping ChenGuangfu JinHongxia MaJuncheng DaiJiaping ChenYue JiangHui WangZhian LiuZhibin HuHongbing ShenIt has been considered that the detection methods for circulating tumor cells (CTCs) based on epithelial cell adhesion molecule (EpCAM) underestimate the number of CTCs and may miss a metastatic subpopulation with cancer stem cell (CSC) properties. Therefore, we investigated EpCAM-positive and -negative CTCs in non-small cell lung cancer (NSCLC) patients at different stages, assessed the clinical value of these CTCs and explored their capacity in the following CSC model.CTCs were enriched by the depletion of leukocytes with bi-antibodies using a magnetic bead separation technique and then identified by the expression of EpCAM and cytokeratin 7 and 8 using multi-parameter flow cytometry. We determined the distribution of CTCs classified by the expression of EpCAM in 46 NSCLC patients with stages I to IV, assessed the diagnostic value of these CTCs by longitudinal monitoring in 4 index patients during adjuvant therapy and characterized the stemness of these CTCs by the expression of CXCR4 and CD133 in 10 patients.EpCAM-negative (E-) CTCs were detected to be significantly higher than EpCAM-positive (E+) CTCs in stage IV (p = 0.003). The patients with the percentage of E-CTCs more than 95% (r > 95%) were detected to be significantly increased from 13.3% in stage I-II to 61.1% in stage IV (p = 0.006). Kaplan-Meier analysis indicated that the patients with r > 95% had significantly shorter survival time than those with r ≤ 0.95 (p = 0.041). Longitudinal monitoring of CTCs indicated that the patients with a high percentage of E-CTCs in the blood were not responsive to either chemotherapy or targeted therapy. Further characterization of CTCs revealed that a stem-like subpopulation of CXCR4+CD133+ CTCs were detected to be significantly more prevalent in E-CTCs than that in E+CTCs (p = 0.005).The enrichment of CTCs by the depletion of leukocytes with bi-antibodies is a valuable method for estimating the number of CTCs, which can be potentially applied in predicting the prognosis, monitoring the therapeutic effect of NSCLC patients and further analyzing the biology of CTCs.http://europepmc.org/articles/PMC4552861?pdf=render |
collection |
DOAJ |
language |
English |
format |
Article |
sources |
DOAJ |
author |
Jian Yin Yi Wang Hanlu Yin Wenping Chen Guangfu Jin Hongxia Ma Juncheng Dai Jiaping Chen Yue Jiang Hui Wang Zhian Liu Zhibin Hu Hongbing Shen |
spellingShingle |
Jian Yin Yi Wang Hanlu Yin Wenping Chen Guangfu Jin Hongxia Ma Juncheng Dai Jiaping Chen Yue Jiang Hui Wang Zhian Liu Zhibin Hu Hongbing Shen Circulating Tumor Cells Enriched by the Depletion of Leukocytes with Bi-Antibodies in Non-Small Cell Lung Cancer: Potential Clinical Application. PLoS ONE |
author_facet |
Jian Yin Yi Wang Hanlu Yin Wenping Chen Guangfu Jin Hongxia Ma Juncheng Dai Jiaping Chen Yue Jiang Hui Wang Zhian Liu Zhibin Hu Hongbing Shen |
author_sort |
Jian Yin |
title |
Circulating Tumor Cells Enriched by the Depletion of Leukocytes with Bi-Antibodies in Non-Small Cell Lung Cancer: Potential Clinical Application. |
title_short |
Circulating Tumor Cells Enriched by the Depletion of Leukocytes with Bi-Antibodies in Non-Small Cell Lung Cancer: Potential Clinical Application. |
title_full |
Circulating Tumor Cells Enriched by the Depletion of Leukocytes with Bi-Antibodies in Non-Small Cell Lung Cancer: Potential Clinical Application. |
title_fullStr |
Circulating Tumor Cells Enriched by the Depletion of Leukocytes with Bi-Antibodies in Non-Small Cell Lung Cancer: Potential Clinical Application. |
title_full_unstemmed |
Circulating Tumor Cells Enriched by the Depletion of Leukocytes with Bi-Antibodies in Non-Small Cell Lung Cancer: Potential Clinical Application. |
title_sort |
circulating tumor cells enriched by the depletion of leukocytes with bi-antibodies in non-small cell lung cancer: potential clinical application. |
publisher |
Public Library of Science (PLoS) |
series |
PLoS ONE |
issn |
1932-6203 |
publishDate |
2015-01-01 |
description |
It has been considered that the detection methods for circulating tumor cells (CTCs) based on epithelial cell adhesion molecule (EpCAM) underestimate the number of CTCs and may miss a metastatic subpopulation with cancer stem cell (CSC) properties. Therefore, we investigated EpCAM-positive and -negative CTCs in non-small cell lung cancer (NSCLC) patients at different stages, assessed the clinical value of these CTCs and explored their capacity in the following CSC model.CTCs were enriched by the depletion of leukocytes with bi-antibodies using a magnetic bead separation technique and then identified by the expression of EpCAM and cytokeratin 7 and 8 using multi-parameter flow cytometry. We determined the distribution of CTCs classified by the expression of EpCAM in 46 NSCLC patients with stages I to IV, assessed the diagnostic value of these CTCs by longitudinal monitoring in 4 index patients during adjuvant therapy and characterized the stemness of these CTCs by the expression of CXCR4 and CD133 in 10 patients.EpCAM-negative (E-) CTCs were detected to be significantly higher than EpCAM-positive (E+) CTCs in stage IV (p = 0.003). The patients with the percentage of E-CTCs more than 95% (r > 95%) were detected to be significantly increased from 13.3% in stage I-II to 61.1% in stage IV (p = 0.006). Kaplan-Meier analysis indicated that the patients with r > 95% had significantly shorter survival time than those with r ≤ 0.95 (p = 0.041). Longitudinal monitoring of CTCs indicated that the patients with a high percentage of E-CTCs in the blood were not responsive to either chemotherapy or targeted therapy. Further characterization of CTCs revealed that a stem-like subpopulation of CXCR4+CD133+ CTCs were detected to be significantly more prevalent in E-CTCs than that in E+CTCs (p = 0.005).The enrichment of CTCs by the depletion of leukocytes with bi-antibodies is a valuable method for estimating the number of CTCs, which can be potentially applied in predicting the prognosis, monitoring the therapeutic effect of NSCLC patients and further analyzing the biology of CTCs. |
url |
http://europepmc.org/articles/PMC4552861?pdf=render |
work_keys_str_mv |
AT jianyin circulatingtumorcellsenrichedbythedepletionofleukocyteswithbiantibodiesinnonsmallcelllungcancerpotentialclinicalapplication AT yiwang circulatingtumorcellsenrichedbythedepletionofleukocyteswithbiantibodiesinnonsmallcelllungcancerpotentialclinicalapplication AT hanluyin circulatingtumorcellsenrichedbythedepletionofleukocyteswithbiantibodiesinnonsmallcelllungcancerpotentialclinicalapplication AT wenpingchen circulatingtumorcellsenrichedbythedepletionofleukocyteswithbiantibodiesinnonsmallcelllungcancerpotentialclinicalapplication AT guangfujin circulatingtumorcellsenrichedbythedepletionofleukocyteswithbiantibodiesinnonsmallcelllungcancerpotentialclinicalapplication AT hongxiama circulatingtumorcellsenrichedbythedepletionofleukocyteswithbiantibodiesinnonsmallcelllungcancerpotentialclinicalapplication AT junchengdai circulatingtumorcellsenrichedbythedepletionofleukocyteswithbiantibodiesinnonsmallcelllungcancerpotentialclinicalapplication AT jiapingchen circulatingtumorcellsenrichedbythedepletionofleukocyteswithbiantibodiesinnonsmallcelllungcancerpotentialclinicalapplication AT yuejiang circulatingtumorcellsenrichedbythedepletionofleukocyteswithbiantibodiesinnonsmallcelllungcancerpotentialclinicalapplication AT huiwang circulatingtumorcellsenrichedbythedepletionofleukocyteswithbiantibodiesinnonsmallcelllungcancerpotentialclinicalapplication AT zhianliu circulatingtumorcellsenrichedbythedepletionofleukocyteswithbiantibodiesinnonsmallcelllungcancerpotentialclinicalapplication AT zhibinhu circulatingtumorcellsenrichedbythedepletionofleukocyteswithbiantibodiesinnonsmallcelllungcancerpotentialclinicalapplication AT hongbingshen circulatingtumorcellsenrichedbythedepletionofleukocyteswithbiantibodiesinnonsmallcelllungcancerpotentialclinicalapplication |
_version_ |
1725355864677679104 |